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Background: Despite major advances in drug development, effective cardiovascular therapies and suitable
cardiovascular biomarkers remain limited. The aim of this study was to leverage mass spectrometry (MS) based
peptide profiling strategies to identify changes that occur in peptidomic profiles of rat plasma following coronary
artery ligation generated myocardial infarction (MI).
Methods: One week after MI, rats were randomized to receive either an ACE inhibitor (ramipril, Ram-1 mg/kg/day),
or vehicle (Veh) for 12 weeks. Echocardiography and hemodynamic measurements were made before sacrifice and
plasma collection. High abundance proteins were depleted with affinity capture before MS profiling. Differentially
expressed peptide ions were identified using proprietary software (ClinProtTools).
Results: MI increased heart/body weight (18%), lung/body weight (56%), and left ventricular (LV) end diastolic
pressure (LVEDP, 247%); and significantly reduced percentage fractional shortening (FS, 75%) and rate of pressure
rise in the LV (dP/dtmax, 20%). Ram treatment significantly attenuated the changes in LVEDP (61%) and FS (27%).
Analysis of MALDI-ToF generated mass spectra demonstrated that peptide ions 1271, 1878, 1955, 2041 and 2254 m/z
were consistently decreased by Ram treatment (p< 0.001) and thus may be associated with the agent’s therapeutic
effects. Among peptides that were significantly changed, synapsin-2, adenomatous polyposis coli protein and
transcription factor jun-D were identified as significantly reduced by Ram treatment.
Conclusions: This approach allows us to screen for potential biomarkers in a window of the blood proteome that
previously has been difficult to access. The data obtained from such an approach may potentially useful in prognosis,
diagnosis, and monitoring of treatment response.
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Despite the advancesment in the development of effective
therapies for cardiovascular diseases (CVDs), their socioe-
conomic and human costs continue to escalate throughout
the world, with an aging population. The number of effect-
ive cardiovascular therapies and viable therapeutic targets
remains surprisingly limited. The number of clinically* Correspondence: g.rice@uq.edu.au
2Centre for Clinical Research, University of Queensland, Bld 71/918, Royal
Brisbane and Women’s Hospital, Herston, QLD 4032, Australia
Full list of author information is available at the end of the article
© 2012 Wang et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is puseful cardiovascular biomarkers is even fewer [1]. As most
CVDs directly impact expression and function of circulat-
ing proteins and peptides, the likelihood of identifying
CVD-associated changes within this system is significant.
Considerable insight has emerged over the past few dec-
ades with regard to cellular and molecular derangements
within the myocardium. Analysis of gene expression, while
a powerful tool, often reveals a poor correlation with the
quantity of corresponding functional protein. This is prob-
ably related to the divergent time course of gene expres-
sion in relation to protein expression, regulation andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ment of other factors. Given the rapid advances in prote-
omic profiling over the last few years, recent editorials
have called for direct and large-scale analysis of proteins
within the failing myocardium where significant informa-
tion may be gained from proteomic approaches [2-4].
With the wide array of cellular dysfunction observed in
failing myocardium in the whole animal setting as well as
derangements in individual cell types, it is expected that
there will be considerable differences in peptide profiles be-
tween normal and dysfunctional myocardium. Indeed,
peptide profiling approaches (peptidomics) to identify
disease- and treatment-associated changes are delivering
novel insights [5,6].
In the current study, mass spectrometry-based peptide
profiling strategies were utilized to identify and characterize
changes in the peptidomic profiles of blood associated with
myocardial infarction (MI) and heart failure (HF). We
employed an experimental animal model of the disease
aiming to identify characteristic peptidomic profiles that
may be useful for disease prognosis, diagnosis and/or mon-
itoring of treatment response. The approach we have devel-
oped allows screening for biomarkers of MI and HF in a
window of the blood proteome that previously has been
difficult to access with conventional proteomic strategies.
The strength of this approach is that we also have the op-
portunity to simultaneously identify peptide peaks detected
at differential levels.
Considering the natural variability expected between
human samples due to back gound therapies, to adequately
test hypotheses relating to changes in plasma peptidomic
profiles during disease progress and in response to specific
treatment regimens, a proven animal model of disease is
essential. Animal models of MI involving ligation of the left
anterior descending (LAD) coronary artery have been
widely used for studies of functional and therapeutic effects
in left ventricle remodeling and HF. Our laboratory has
established and routinely performed studies with this
model of post-MI HF in rats [7-10]. We have previously
demonstrated beneficial effects of p38-MAPK inhibition on
left ventricular remodeling and cardiac function in this HF
model [7,8]. We, therefore, have used this model to define
temporal changes in peptidomic profiles during disease
progression.
Current therapeutics, such as angiotensin-converting en-
zyme (ACE) inhibitors, attenuate left ventricle remodeling
in both animal models and in patients with post-MI and
HF [8,11-14]. ACE inhibitors can prevent cardiac myocyte
hypertrophy and cardiac fibrosis, reduce ventricular dila-
tion and cardiac dysfunction and prolong survival after MI
[7,8,11-13]. Therefore, treatment of post-MI rats with the
ACE inhibitor, ramipril (Ram), provides an ideal model for
investigating potential changes in peptide profiles that may
be indicative of therapeutic benefits and/or drug inducedresponses. The primary hypotheses to be tested in this
study were: that post-MI rats which develop HF display
altered plasma peptide profiles; and that therapy with the
ACE inhibitor ramipril (Ram) may reverse/affect such
changes.
Method and materials
The authors of this manuscript have certified that they
comply with the Principles of Ethical Publishing in the
International Journal of Cardiology: Shewan LG and Coats
AJ. Ethics in the authorship and publishing of scientific
articles. Int J Cardiol 2010;144:1–2.
Study design
Myocardial infarction experimental protocol and blood
sample collection
Female Sprague Dawley rats (180–220 g) underwent cor-
onary artery ligation under anesthesia as previously
described [8]. One week after myocardial infarction (MI)
rats were randomized to receive either an angiotensin
converting enzyme inhibitor (Ram – 1 mg/kg, MI +Ram),
or vehicle (0.5% methylcellulose, MI +Veh) by gavage,
daily for 12 weeks. The control group consisted of sham-
operated animals (Sham) without coronary artery ligation
receiving vehicle for 12 weeks. At the end of the treatment
period, echocardiographic images were obtained and
hemodynamic measurements by cardiac catheterization
were recorded prior to animal sacrifice and tissue collec-
tion. All experiments were performed in accordance with
the Australian National Health and Medical Research
Council, Code of Practice for the Care and Use of Animals
for Scientific Purposes (7th edition, 2004), with approval of
the AMREP Animals Ethics Committee at the Alfred
Hospital.
Echocardiography and cardiac catheterization
Echocardiography was performed in lightly anaesthetized
animals (ketamine 40 mg/kg, xylazine 5 mg/kg, i.p.) after
12 weeks treatment using a HP Sonos 5500 with a 12 MHz
probe (Agilent Technologies, Palo Alto, CA, USA). Two-
dimensional and m-mode images at the mid-papillary
muscle level were used to obtain LV internal diameters in
systole (LVIDs) and diastole (LVIDd) which were measured
offline and % LV fractional shortening determined [8].
Following final echocardiography, animals were sedated
with pentobarbitone (50 mg/kg, ip) and hemodynamic mea-
surements of central aortic pressure (CAP), systolic (SBP)
and diastolic (DBP) blood pressure, heart rate (HR), LV end-
diastolic pressure (LVEDP), and the maximal (dP/dtmax) and
minimal (dP/dtmin) first derivative of left ventricular pres-
sure were obtained using a pressure transducer (UFI, model
1050, Morro Bay, CA, USA) connected to a MacLab sys-
tem (ADInstruments, Castle Hill, NSW, Australia)[8]. On
completion of these measurements the heart and lungs
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centrifuged at 4°C, 3000RPM for 15 min. Plasma aliquots
were frozen and stored at −80°C for proteomic studies.
Statistical analysis for functional data
Integrated Peak Area (IPA) is expressed as mean±SEM,
with 8 animals in each group. Differences between groups
were compared using an ANOVA, p values< 0.05 were
considered statistically significant.
Removal of high abundance proteins
Prior to analysis, high abundance proteins were removed
using Affi-Gel Blue and Protein A (Bio-Rad) [15]. Plasma
samples (60μL, 60–80 mg protein/mL) were diluted in
180μL 20 mM phosphate buffer (pH7.0). Diluted plasma
was then incubated with 400μL Affi-Gel Blue (Bio-Rad La-
boratories, Hercules, CA) and 60μL Affi-Gel Protein A
(Bio-Rad) for 30 min at room temperature in a micro-spin
column (Bio-Rad). Samples were mixed every 5 min. Fol-
lowing incubation the flow-through (under gravity) was
collected (~200μL) and stored at −80°C for protein deter-
mination and analysis.
Sample preparation with solid phase extraction
High-abundance protein depleted plasma supernatants
(100μL, 250–300μg protein) were cleaned up using solid
phase extraction (SPE). The SPE plates were Oasis HLB μelu-
tion plates (Waters Corporation, Milford, MA) containing a
water-wettable reversed phase polymer (poly(divinylbenzene-
co-N-vinylpyrrolidone)) also referred to as hydrophilic-
lipophilic-balanced (HLB), as previously reported by
other groups. [16,17] Briefly, the SPE plate was condi-
tioned (methanol, 300μL); followed by 300μL, 75%:0.1%,
acetonitrile:formic acid (ACN:FA), then equilibrated
(ACN:FA, 2%:0.1%, 300μL). Depleted plasma (100μL) was
acidified with FA (100%, 1μL) and applied to the wells.
Wells were washed (6 times, ACN:FA, 2%:0.1%, 300μL)
and protein was eluted (ACN:FA, 60%:0.1%, 50μL) into a
new microtitre plate (Greiner, Stonehouse, UK).
Peptide profiling mass spectrometry
Samples eluted from SPE plates were analyzed using
MALDI-ToF mass spectrometry (Autoflex II, ToF/ToF,
Bruker Daltonics, Bremen, Germany) in linear-positive
mode equipped with a 337 nm nitrogen laser and 2 GHz
digitizer. Each SPE eluted sample was applied to the target-
plate in quadruplicate, assuring 4 independent measure-
ments of each sample. Mass spectra were collected under
20 kV of ion acceleration with the ion deflection at mass≤
1000 m/z and time lag focusing at 120 nanoseconds. The
mass range was calibrated using a calibration mixture
[angiotensin I (1296.684), angiotensin II (1046.541), sub-
stance P (1347.735), bombesin (1619.822), ACTH clip1-17
(2093.086), ACTH clip18–39 (2465.198), somatostatin 28(3147.471), insulin (5734.52), ubiquitin (8565.76)]. Spectral
data was collected in automatic acquisition mode over an
m/z range of 1000–10,000 m/z using the “AutoXecute”
function (FlexControl ™, version 2.2). Thirty-three sets of
30 shots (at 25 Hz frequency) were collected to give a com-
prehensive coverage for each sample spot. Each spectrum
represents the average of 990 laser shot at a fixed laser en-
ergy output.
Data analysis of peptidomic profiles
Raw spectral files were submitted to proprietary software
(ClinProtTools, v2.0, Bruker Biosciences) to identify peptide
ions detected at differentially expressed levels. ClinProTools
generates pattern recognition models for classification and
prediction and allows graphical visualization of the pro-
cessed spectral profiles and generation of statistical classifi-
cation models. The program prepares the spectral data
using a series of standard processing steps; baseline sub-
traction, normalization, recalibration, calculation of Total
Average Spectrum (TAS), calculation of peak area on TAS,
calculation of area of each peak and normalization of peak
areas. Peak statistics are generated from the processed data.
The peak comparison output represents (i) peak intensity
and (ii) 2D peak distribution standard deviation envelopes
(95% confidence interval). Spectral data presented repre-
sent mean peak intensity and a threshold signal-to-noise
ratio of 30 (based upon the averaged spectra) was used for
peptide peak definition.
Peptide identification – LC MS/MS
The peptides eluted from SPE were pooled and dried in a
vacuum centrifuge. These were resuspended in 20μL of 2%
ACN/0.1% FA and 8μL was applied to a C18 RP ProteoCol
trap cartridge (10 mm×150 μm, 300 Å pore size, SGE Ana-
lytical Science, Victoria, Australia) using an Agilent 1100 ca-
pillary HPLC (Agilent, Foster City, CA) coupled to a 3D
ion-trap mass spectrometer (HCT Ultra, Bruker Daltonics).
The column was equilibrated with Buffer A (Buffer A:
0.1%FA, 10mins, Flow rate 4μL/min) prior to gradient
separation (2–60%) using Buffer B (90%ACN/0.1%FA,
4μL/min). Buffer B was then increased over 5mins from
60–100% and was held for 5 min at 100%B before redu-
cing to initial conditions (100% Buffer A, 5mins) and
holding for a further 5 min. The ion trap was used in
standard scan mode. Total ion current chromatograms
and MS/MS mass spectra were acquired using Esquire
control interface (Bruker Daltonics). Tandem mass spec-
tra were extracted using DataAnalysis (Bruker Daltonics,
Version 3.3). Biotools software (Bruker, Version 3.1) and
the Mascot search engine (Matrix Science, London, UK;
version 2.2) were used to interrogate the SwissProt data-
base (Release 57.12). Search parameters were: Taxonomy:
Rat; parent ion mass tolerance: 2.4 Da; fragment ion tol-
erance: 1.2 Da; Missing Cleavages: 0; Enzyme: none;
Table 2 Echocardiography and Hemodynamic assessment
Sham (n= 8) MI + Veh (n = 8) MI + Ram (n= 8)
Echocardiography data
LVIDs (cm) 0.43 ± 0.02 0.89 ± 0.02 *** 0.77 ± 0.02 ###
LVIDd (cm) 0.69 ± 0.01 0.99 ± 0.01 *** 0.94 ± 0.02 #
%FS 38.6 ± 2.1 9.8 ± 1.3 *** 17.2 ± 2.0 #
Hemodynamic data
CAP (mmHg) 127.6 ± 1.7 117.1 ± 5.1 104.3 ± 3.4
SBP (mmHg) 146.9 ± 4.0 132.5 ± 4.4 120.1 ± 2.5 #
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package (Bioinformatics Solutions, Waterloo, Ontario,
Canada) was also used to analyze MS/MS data. The Bruker
analysis.yep file was imported directly into Peaks. Mass
spectral data was preprocessed with filter quality was set at
>0.65, charge options 1–3, and with other options appro-
priate for the Bruker Ion Trap. The processed data were
used to search the SwissProt database (Release 57.9).
Search parameters were: Taxonomy: Rat; parent ion mass
tolerance: 2.4 Da; fragment ion tolerance: 0.8 Da; Max
missed cleavages: 100; Enzyme: none; Variable Modifica-
tions: Oxidation (M); Max variable PTM per peptide: 3.
Peptide identified via Peaks and Mascot search engines
masses were match with masses identified from the
MALDI-ToF profiles via ClinProTools with a signal to
noise 15:1.
Results
Organ weights and infarct size
There were no significant increases in heart weight to body
weight ratio (HW/BW) amongst the groups, however a
strong trend toward increased hypertrophy (18%) was
observed in MI+vehicle animals compared to sham animals.
Ram treatment attenuated this increase of hypertrophy
(Table 1). Lung weight to body weight ratio (LW/BW) was
increased significantly by 56% in MI vehicle animals, indi-
cative of the pulmonary congestion that accompanies heart
failure. Ram attenuated this increase in LW/BW (Table 1).
Infarct sizes were similar between the MI groups (Table 1).
Echocardiography and hemodynamic parameters
Percentage fractional shortening (FS) was reduced by 75%
in MI+Veh animals; treatment with Ram significantly atte-
nuated this reduction by 26% (Table 2). LVIDs and LVIDd
were increased in MI+Veh animals by 107% and 43% re-
spectively; treatment with Ram significantly attenuated the
increase in LVIDs and LVIDd by 26% and 17% respectively
(Table 2).
Hemodynamic analyses revealed no significant differ-
ences in central aortic, systolic and diastolic blood pressure
between the groups. MI+Veh animals had a lower bloodTable 1 Tissue, Body weights and Infarct Size
Sham (n= 8) MI +Veh (n = 8) MI + Ram(n= 8)
Body weight (g) 292 ± 5 291 ± 5 307 ± 10
Heart weight (g) 0.92 ± 0.02 1.09 ± 0.11 1.03 ± 0.06
Lung weight (g) 1.06 ± 0.02 1.65 ± 0.29 * 1.22 ± 0.12
HW/BW (mg/g) 3.16 ± 0.06 3.75 ± 0.32 3.34 ± 0.10
LW/BW (mg/g) 3.63 ± 0.10 5.66 ± 0.94 * 3.98 ± 0.41
Infarct Size (%) — 50.7 ± 3.8 50.2 ± 1.9
Data are expressed as mean ± SEM, * P< 0.05 compared to sham animals, n = 8
in each group. HW/BW: heart weight/body weight; LW/BW: lung
weight/body weight.pressure compared to the sham group but this was not sig-
nificant. Ram treatment significantly reduced systolic blood
pressure further by 9.4% compared to MI+Veh animals
(P< 0.05; Table 2).
LVEDP was increased by 225% in MI+Veh animals com-
pared to the sham group, Ram treatment reduced this in-
crease by 57% (P< 0.05; Table 2). dP/dtmax and dP/dtmin
were reduced in MI+Veh animals by 18% and 21% respect-
ively compared to the sham group (P< 0.05; Table 2), Ram
treatment showed slight improvement of these measures
but did not reach significance (Table 2).
Thus, 3 months post-MI, the MI+Veh group had devel-
oped HF while treatment with Ram significantly improved
cardiac function providing an ideal HF animal model for
peptidomic profiling.
Protein depletion
Total protein was determined before and after Affi-Gel
Blue/Protein A depletion of whole plasma. Values aver-
aged 44.69 ± 8.36 mg/ml protein (before depletion) and
0.94 ± 0.15 mg/ml protein (after depletion). This repre-
sents an average depletion of approximately 83% of total
protein per sample.
Peptide profile analysis
The primary hypothesis to be tested in this study was that
post-MI rats that developed HF display altered plasma pep-
tide profiles. Plasma samples (24 total, n =8 for controls,
MI+Veh and MI+Ram) were subjected to Affi-Gel blue
and Protein A for removal of high abundance proteinsDBP (mmHg) 106.8 ± 3.3 102.0 ± 6.8 88.9 ± 4.4
HR (beats/min) 348 ± 7 355 ± 29 352 ± 16
LVEDP (mmHg) 2.8 ± 0.7 9.1 ± 1.1 *** 5.5 ± 0.8 #
dP/dtmax (mmHg/s) 5898 ± 165 4819 ± 274 * 5156 ± 115
dP/dtmin (mmHg/s) −5851 ± 161 −4637 ± 329 ** −5021 ± 159
LVIDs – left ventricular internal diameter in systole; LVIDd – left ventricular
internal diameter in diastole; %FS – percentage fractional shortening; CAP –
central aortic pressure; SBP – systolic blood pressure; DBP – diastolic blood
pressure; HR – heart rate; LVEDP – left ventricular end diastolic blood pressure;
dP/dtmax – rate of left ventricular pressure rise; dP/dtmin – rate of left
ventricular pressure fall.
Data are expressed as mean ± SEM; * P< 0.05, ** P< 0.01, *** P< 0.001
compared to sham animals; # P< 0.05, ### P< 0.001 compared to MI + Veh
animals.
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by mass spectrometry, a mass spectrum was collected for
each sample and a protein profile over the mass range
1000–10,000 m/z was created from the averaged spectra of
each group (Figure 1, data is presented as relative peak in-
tensity versus m/z). When control (sham), disease state
(MI+Veh) and treatment (Ram) were compared predom-
inant peptide peaks were observed in the mass range
1000–5000 m/z.
Statistical analyses
Peptide profiles were generated for plasma samples
obtained from Sham, MI animals (MI+Veh) and MI ani-
mals with treatment of Ram (MI+Ram) and mass spectra
from the MALDI-ToF were analyzed using ClinProTools.Figure 1 Plasma Peptide Profile. Average MALDI TOF mass spectra (over
Samples were AGB depleted plasma from experimental groups sham (n = 8
peak intensity vs. m/z.The average integrated peak area ±SE for 13 selected ion
peaks are presented in Figure 2. This figure indicates some
of the peptides that were detected at differential levels for
rats within the three groups, Sham (n=8), MI+Veh (n=8)
and MI+Ram (n=8). Differences between these ions were
compared based on peak area, with peaks at 1271, 1878,
1955, 2041, 2254, 4519 and 8854 m/z being statistically sig-
nificant between groups (ANOVA, p values< 0.05). In the
MI+Ram group, peptides ion measurements at 1271,
1878, 1955, 2041, 2254, 4519 and 8854 m/z consistently
decreased with Ram treatment when compared to samples
isolated from MI+Veh rats (p <0.05). The peptide at
2798 m/z was elevated in plasma from MI+Ram rats
compared to MI+Veh rats but not statistically significant
between groups. Peptides at 1271, 1878, 1955, 2041, 2254,the range 1000 to 10,000 m/z) of plasma peptides eluted from SPE.
), MI + Veh (n = 8) and MI + Ram (n= 8). Data are presented as relative
Figure 2 Average integrated peak area ± SE for 13 ion peaks from 3 experimental groups; Sham (n= 8), MI + Veh (n = 8) and Ram (n= 8)
is displayed. * indicates statistically significant IPA between all groups (ANOVA, p< 0.05).
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peutic effects of Ram and the peptide at 2798 m/z may be
associated with drug-stimulated effects (Figure 2).
Peptide identifications
In order to determine the identity of the peptides detected
at differential levels, LC-MS/MS ion trap mass spectrom-
etry was used (Bruker Daltonics, Bremen, Germany). Pep-
tide identifications were generated using both Mascot and
Peaks software packages. The differentiated expressed pep-
tides identified include Synapsin-2, Adenomatous polyp-
osis coli protein, Transcription factor jun-D, CaiB/baiF
CoA-transferase family protein C7orf10 homolog, Estradiol
17-beta-dehydrogenase 1, Contrapsin-like protease inhibi-
tor 1 precursor, Regulator of differentiation 1 and Pyrin
(Marenostrin) (Tables 3 and 4).
Discussion
Utilizing novel mass spectrometry-based peptide profiling
strategies developed in our laboratory, we were able to
identify and characterize changes in the peptidomic pro-
files of blood associated with MI and HF in an experimen-
tal animal model of the disease. This approach allows us
to screen for potential biomarkers of MI and HF in a win-
dow of the blood proteome that previously has been diffi-
cult to access due to high abundant proteins masking the
identification of lower concentrations of small peptides. InTable 3 Peptide sequences identified from rat plasma








3661.00 LHRAETMTASELLGIPPGVKEKLHLLYQKSKSAaddition, this approach gives us the ability to identify pep-
tide peaks of interest. The present study demonstrated that
post-MI rats, which developed HF, display altered plasma
peptide profiles when compared to controls. Furthermore,
therapy with ACE inhibitor, Ram, reverses some changes
but also induces additional alteration, presumably related
to its pharmacological effects (Figure 2).
Tandem mass spectrometry allowed us to identify
peptides associated with the development of HF in
post-MI rat. These include synapsin-2, adenomatous
polyposis coli protein, transcription factor jun-D, CaiB/
baiF CoA-transferase family protein C7orf10 homolog,
estradiol 17-beta-dehydrogenase 1, contrapsin-like pro-
tease inhibitor 1 precursor, regulator of differentiation
1 and pyrin (marenostrin) (Table 4). Although identi-
fied for the first time from the post-MI plasma as po-
tential biomarkers for post-MI HF, many of them have
known functional roles in the cardiovascular system.
For example, adenomatous polyposis coli protein has
been reported to play an important role in human car-
diac development and disease. [18] Transcription factor
jun-D is regulated by redox and hypoxia in cardiac
myocytes. [19,20] Furthermore, both adenomatous
polyposis coli protein and transcription factor jun-D
were significantly reduced by the ACE inhibitor, Ram,
in post-MI rat plasma (Figure 2, Tables 3 and 4), indi-


















1955.9184 Q63537 SYN2_RAT Synapsin-2 33
2041.0374 P70478 APC_RAT Adenomatous polyposis coli protein 81
2041.023 P52909 JUND_RAT Transcription factor jun-D 98.6
2799.3203 Q68FU4 CG010_RAT CaiB/baiF CoA-transferase family protein C7orf10 homolog 43.5
3488.7876 P51657 DHB1_RAT Estradiol 17-beta-dehydrogenase 1 34
3503.7307 P05545 CPI1_RAT Contrapsin-like protease inhibitor 1 precursor 51
3503.6377 Q9Z118 ROD1_RAT Regulator of differentiation 1 57
3661.0025 Q9JJ25 MEFV_RAT Pyrin (Marenostrin) 34
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tide changes. It is worth noting that well characterized bio-
markers for HF such as arterial natriuretic peptide (ANP)
and brain natriuretic peptide (BNP) were not in the list of
the potential biomarkers identified in this study. This could
be because these peptides were not isolated using our meth-
ods, that they were below the limits of detection for our
method or that they do not ionize or fragment with suffi-
cient efficiency in the mass spectrometer.
There have been considerable efforts in determining the
protein profile changes in both HF patients and the post-
MI animal model. Several these studies have identified
plasma proteins that are related to cardiovascular func-
tions, including the HUPO plasma proteome project. [21]
This project identified some 3020 proteins from healthy
subjects with a subset of these proteins having cardiovascu-
lar related functions. [21] These proteins include markers
of inflammation and/or cardiovascular disease, vascular
and coagulation, signaling, growth and differentiation, cyto-
skeletal, transcription factors, channels/receptors and heart
failure and remodeling providing a base line database for
the mining of potential biomarkers in the disease stage.
This proteomic approaches have also allowed the discovery
of previous unknown proteins involved in cardiovascular
diseases. The proteomic analysis of plasma from patients
with HF or acute coronary syndrome and other cardiovas-
cular diseases [22-27] identified targets suitable for use as
biomarkers in inflammation, oxidation stress, extracellular-
matrix remodeling, neurohormonal activation, myocyte in-
jury and stress. Proteomic studies utilizing plasma from
acute MI patients have identified cardiac troponin I and
α1-chain of haptoglobin from patients as potential biomar-
kers for acute MI and predictors of cardiac remodeling.
[28,29] Proteomic analyses using left ventricular tissue from
post-MI animals have identified the substrates for matrix
metalloproteinases (MMP7 and MMP9). [30,31] This
study, however, is the first to specifically identify small mo-
lecular weight peptides that are related to post-MI develop-
ment of HF and therapeutic response of ACE inhibition
with Ram in this animal model.The major difficulty in mining low abundance biomar-
kers from plasma or serum is the presence of a small num-
ber of proteins including albumin, α2-macroglobulin,
transferrin and immunoglobulin, that represent as much
as 80% of the total protein. The high abundance of these
proteins makes it difficult to identify lower abundance pro-
tein in plasma using traditional proteomic techniques.
Much of the literature on plasma biomarker identification
relates to relatively high abundance, high mass proteins
identified with conventional proteomic techniques. The
existing opportunities to identify signature changes in sub-
sets of lower abundance peptides that may be informative
of disease stage remain relatively under-explored. Hence,
we have developed a mass spectrometry-based peptide
profiling strategy to identify and characterize changes in
small molecular weight peptides from plasma samples.
The strength of this approach is that it affords opportunity
to identify (at the same time) differentially expressed pep-
tide peaks. This provides considerable advantage over con-
ventional approaches where most often the large high
abundance proteins are identified.
Conclusions
The results from this study may potentially be useful in
prognosis, diagnosis, and monitoring the treatment re-
sponse with experimental animal models of MI and HF.
The data obtained may be utilized in three ways (i) as com-
ponents within a multivariate classification model that may
be used as a prognostic or diagnostic test; as the identity of
the contributing peptides can be determined (ii) specific
multiplex immunoassays developed to provide quantitative
endpoints and potentially monitor changes with thera-
peutic intervention; (iii) to increase our understanding of
the etiology of cardiovascular disease complications.
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